Scancell Holdings plc (AIM:SCLP)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 103.04M +0.8% |
| Revenue (ttm) | n/a |
| Net Income | -17.90M |
| EPS | -0.17 |
| Shares Out | 121.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 433,192 |
| Open | 86.50 |
| Previous Close | 86.40 |
| Day's Range | 85.00 - 87.00 |
| 52-Week Range | 85.00 - 295.00 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 300.00 (+252.94%) |
| Est. Earnings | Nov 4, 2026 |
About Scancell Holdings
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company’s product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+ that is in Phase III for the treatment of melanoma; and SC134, an a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SCLP stock is "Strong Buy." The 12-month stock price target is 300p, which is an increase of 252.94% from the latest price.
News
Scancell Holdings Annual report: H2 2026
Scancell Holdings has published its H2 2026 annual report on October 9, 2026.
Scancell Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The session highlighted strong phase II results for iSCIB1+ in advanced melanoma, a robust regulatory and financial position post-merger, and a clear path to phase III and commercial expansion. Multiple pipeline assets and near-term catalysts support growth and collaboration.
Scancell Holdings Slides: Corporate presentation
Scancell Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additi...
Scancell Holdings Earnings Call Transcript: H1 2026
Lead asset iSCIB1+ achieved 74% PFS at 16 months in melanoma, with FDA phase III clearance and strong patent protection. Cash runway extends into H2 2026, with multiple financing and partnering options under evaluation. Blockbuster market potential and diversified pipeline support long-term growth.
Scancell Holdings Quarterly report: H1 2026
Scancell Holdings has published its H1 2026 quarterly earnings report on January 29, 2026.
Scancell Holdings Slides: H1 2026
Scancell Holdings has posted slides in relation to its H1 2026 quarterly earnings report, which was published on January 29, 2026.
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-poin...
Scancell Holdings Transcript: Study update
Phase II SCOPE study of iSCIB1+ in advanced melanoma showed a 74% PFS at 16 months and strong disease control, with favorable safety and robust T cell responses. Regulatory agencies support phase III plans, and commercialization is targeted for late 2029.
Scancell Holdings Press release: Study update
Scancell Holdings issued a press release on December 11, 2025, disclosing material business information to investors.
Scancell Holdings Slides: Study update
Scancell Holdings has posted slides in relation to its latest quarterly earnings report, which was published on December 11, 2025.
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a b...
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety
PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies.
PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
GOLDEN, Colo.--(BUSINESS WIRE)--Positive data announced for first stage of Phase 2 trial for advanced melanoma DNA vaccine delivered by the PharmaJet Stratis needle-free system.